The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Ozempic, a diabetes drug, shows promise for liver disease. Research indicates it can reverse non-alcoholic steatohepatitis. A ...

Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.

A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction ...

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

Results showed that 62.9% of patients on Ozempic saw a reduction in liver inflammation, compared to 34.3% on placebo.